Showing 719 results
-
Media Release /-- LCZ696 significantly reduced cardiovascular deaths in head to head study against enalapril, in addition to current best treatment, in patients with HF-REF-- PARADIGM-HF is the largest heart…
-
Media Release /
-
Media Release /- Results of two Phase III psoriasis studies show secukinumab, the first psoriasis IL-17A inhibitor filed with regulatory bodies, met all co-primary and key secondary endpoints[1]- A statistically…
-
Media Release /
-
Media Release /- Designation supports the advancement of CTL019 to help address the unmet need of patients with relapsed/refractory acute lymphoblastic leukemia (r/r ALL)- The filing was submitted by the University…
-
Media Release /
-
Media Release /The study met the primary endpoint with objective response rates of 41.8% and 32.5% respectively in the 200 mg and 800 mg treatment arms(1,2)Basal cell carcinoma is the most common form of skin…
-
Media Release /
-
Media Release /Pivotal data in ALK+ NSCLC for Zykadia™; recently approved by US FDA, marking fastest oncology approval under Breakthrough Therapy designationFirst presentation of pivotal data from Phase III trial…
-
Media Release /
